Changes of Bone-biomarker According to the Severity of Spinal Cord Injury.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 64
- Locations
- 1
- Primary Endpoint
- Serum sclerostin level
Study Overview
Brief Summary
Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed. In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high therapeutic effect as an inhibitor of bone resorption while promoting bone formation. However, there are a few research concerning sclerostin of spinal cord injuries patients. Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •spinal cord injury patients
- •Functional ambulatory category index of 3 or less
Exclusion Criteria
- •history of using bone absorption medication within the effective period
Outcomes
Primary Outcomes
Serum sclerostin level
Time Frame: 1 year
Serum sclerostin level in spinal cord injury patients
Secondary Outcomes
No secondary outcomes reported
Investigators
Dong Gyu Lee
Assistant professor
Yeungnam University Hospital